Screener
McKesson MCK North American Pharmaceutical — Exit and other-related costs
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by McKesson in its filing.
Tagged under the XBRL concept us-gaap:BusinessExitCosts1.
The source filing: McKesson’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:29 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000927653-26-000234
| (In millions) | Three Months Ended June 30, 2026 / North American Pharmaceutical (1) | Three Months Ended June 30, 2026 / Prescription Technology Solutions (1) | Three Months Ended June 30, 2026 / Medical-Surgical Solutions (1) | Three Months Ended June 30, 2026 / Corporate (1) | Total |
|---|---|---|---|---|---|
| Severance and employee-related costs, net | — | $11 | $14 | $7 | $32 |
| Exit and other-related costs (2) | 1 | 10 | 9 | 37 | 57 |
| Asset impairments and accelerated depreciation | 1 | 40 | — | 6 | 47 |
| Total | $2 | $61 | $23 | $50 | $136 |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is McKesson's north american pharmaceutical — exit and other-related costs?
- McKesson (MCK) reported north american pharmaceutical — exit and other-related costs of $1M in Q2 2026.
- How has McKesson's north american pharmaceutical — exit and other-related costs changed year-over-year?
- McKesson's north american pharmaceutical — exit and other-related costs decreased by 0.0% year-over-year, from $1M to $1M.
- What is the long-term trend for McKesson's north american pharmaceutical — exit and other-related costs?
- Over 2 years (2024 to 2026), McKesson's north american pharmaceutical — exit and other-related costs has grown at a 0.0% compound annual growth rate (CAGR), from $3M to $3M.
- What does north american pharmaceutical — exit and other-related costs mean?
- This metric captures costs associated with exiting specific business activities, facilities, or geographic markets within the North American Pharmaceutical segment. It includes lease terminations, contract exit fees, and other non-recurring expenses tied to strategic business closures.
Ask your AI about McKesson's north american pharmaceutical — exit and other-related costs.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude